|
Fusion 3D gross sampling method to overcome heterogeneity in clear cell renal cell carcinoma (ccRCC) and grading angiogenic versus immune signatures. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Bristol Myers Squibb; Ipsen; Novartis; Pfizer |
Speakers' Bureau - AstraZeneca; Bristol Myers Squibb; Novartis; Pfizer; Pierre Fabre |
Research Funding - Novartis (Inst); Pfizer (Inst); Roche (Inst); Seqirus (Inst) |
Expert Testimony - Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Ipsen; MSD Oncology; Novartis; Pfizer/EMD Serono; Pierre Fabre |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; General Electric; Ipsen; Merck Serono; MSD Oncology; Pfizer |
Expert Testimony - EUSA Pharma; Pfizer |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche |
|
|
Consulting or Advisory Role - Astellas Oncology; Bayer; Janssen; Merck; MSD; Pfizer |
Travel, Accommodations, Expenses - Astellas Oncology; Bayer; Janssen |